Author’s response to reviews

Title: Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria

Authors:

Monika Russel-Szymczyk (zmns@novonordisk.com; bmoore@dresources.com)
Vasil Valov (vasv@novonordisk.com)
Alexandra Savova (alex_savova@mail.bg)
Manoela Manova (manoela_manova@yahoo.com)

Version: 4 Date: 21 Nov 2019

Author’s response to reviews:

Dear Editor in Chief,

On behalf of my co-authors, please find below the point-by-point response to the editorial comments.

Editor Comments:

1. In the section 'Funding', please also describe the role of the funding body/bodies in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Response: We have implemented this accordingly.

2. Please remove the point by point response from the manuscript, as it is no longer required at this stage.

Response: This error has been rectified, thank you.

3. Please remove the funding information from the Acknowledgements and include it in the Funding section instead. If you have no further acknowledgements please put “Not Applicable” in the Acknowledgements section.

Response: Implemented.

Yours faithfully,
Monika Russel-Szymczyk
Novo Nordisk Sp. z o.o.,
Uł. Krakowiaków 46
PL 02-255 Warsaw
Poland
zmns@novonordisk.com